ABY-029

DRUG5 trials

Sponsors

Dartmouth-Hitchcock Medical Center

Conditions

GliomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaIntracranial TumorPrimary Soft-tissue Sarcoma

Early Phase 1

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

CompletedNCT02901925

Dartmouth-Hitchcock Medical CenterGlioma

Start: 2017-02-13End: 2021-06-29Updated: 2024-12-13

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

CompletedNCT03154411

Dartmouth-Hitchcock Medical CenterPrimary Soft-tissue Sarcoma

Start: 2017-08-30End: 2020-12-10Updated: 2021-08-30

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

CompletedNCT03282461

Dartmouth-Hitchcock Medical CenterHead and Neck Cancer

Start: 2018-01-24End: 2020-12-18Updated: 2023-05-18

Phase 1

ABY-029 Glioma Trial

RecruitingNCT07063693

Dartmouth-Hitchcock Medical CenterIntracranial Tumor

Start: 2026-02-17End: 2028-12-31Target: 33Updated: 2026-03-10

ABY-029 Head & Neck Trial

Not yet recruitingNCT07279116

Dartmouth-Hitchcock Medical CenterHead and Neck Squamous Cell Carcinoma

Start: 2026-06-30End: 2028-06-30Target: 24Updated: 2026-05-07